Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 51
- Market Cap
- $566M
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
SentiSense also tracks daily options readings for Contineum Therapeutics, Inc. Class A Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Contineum Therapeutics, Inc. Class A Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.